Zacks Research Issues Positive Estimate for CPRX Earnings

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Investment analysts at Zacks Research upped their Q1 2025 earnings per share (EPS) estimates for shares of Catalyst Pharmaceuticals in a note issued to investors on Wednesday, March 19th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn $0.49 per share for the quarter, up from their prior estimate of $0.44. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q2 2025 earnings at $0.51 EPS, Q3 2025 earnings at $0.49 EPS, Q4 2025 earnings at $0.53 EPS, Q1 2026 earnings at $0.57 EPS, Q2 2026 earnings at $0.55 EPS and Q4 2026 earnings at $0.57 EPS.

Other analysts also recently issued research reports about the company. Stephens restated an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Finally, Robert W. Baird lifted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $32.29.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $24.23 on Friday. Catalyst Pharmaceuticals has a 52 week low of $14.47 and a 52 week high of $24.64. The firm has a market cap of $2.94 billion, a price-to-earnings ratio of 20.53, a P/E/G ratio of 3.31 and a beta of 0.84. The business’s 50-day simple moving average is $22.39 and its 200-day simple moving average is $21.62.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now owns 68,873 shares of the company’s stock, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Summit Investment Advisors Inc. lifted its stake in Catalyst Pharmaceuticals by 5.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 580 shares in the last quarter. Bank of Montreal Can lifted its stake in Catalyst Pharmaceuticals by 6.2% in the 4th quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company’s stock valued at $311,000 after acquiring an additional 875 shares in the last quarter. Rhumbline Advisers lifted its stake in Catalyst Pharmaceuticals by 0.3% in the 4th quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company’s stock valued at $6,518,000 after acquiring an additional 952 shares in the last quarter. Handelsbanken Fonder AB raised its holdings in Catalyst Pharmaceuticals by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company’s stock worth $740,000 after acquiring an additional 1,000 shares in the last quarter. Finally, PDT Partners LLC raised its holdings in Catalyst Pharmaceuticals by 5.2% during the fourth quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company’s stock worth $431,000 after acquiring an additional 1,030 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.